123 related articles for article (PubMed ID: 28351335)
1. Prostate-specific membrane antigen-directed nanoparticle targeting for extreme nearfield ablation of prostate cancer cells.
Lee SS; Roche PJ; Giannopoulos PN; Mitmaker EJ; Tamilia M; Paliouras M; Trifiro MA
Tumour Biol; 2017 Mar; 39(3):1010428317695943. PubMed ID: 28351335
[TBL] [Abstract][Full Text] [Related]
2. A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer.
Elsässer-Beile U; Wolf P; Gierschner D; Bühler P; Schultze-Seemann W; Wetterauer U
Prostate; 2006 Sep; 66(13):1359-70. PubMed ID: 16894535
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
[TBL] [Abstract][Full Text] [Related]
4. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
5. PSMA ligand conjugated PCL-PEG polymeric micelles targeted to prostate cancer cells.
Jin J; Sui B; Gou J; Liu J; Tang X; Xu H; Zhang Y; Jin X
PLoS One; 2014; 9(11):e112200. PubMed ID: 25386942
[TBL] [Abstract][Full Text] [Related]
6. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
Huang X; Bennett M; Thorpe PE
Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
[TBL] [Abstract][Full Text] [Related]
8. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen.
Slovin SF
Expert Opin Ther Targets; 2005 Jun; 9(3):561-70. PubMed ID: 15948673
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies for prostate cancer against the prostate specific membrane antigen.
Elsässer-Beile U; Bühler P; Wolf P
Curr Drug Targets; 2009 Feb; 10(2):118-25. PubMed ID: 19199907
[TBL] [Abstract][Full Text] [Related]
10. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
11. Antibody recruiting small molecules: a new option for prostate tumor therapy by PSMA targeting.
Küchenthal CH; Maison W
Chembiochem; 2010 May; 11(8):1052-4. PubMed ID: 20432428
[No Abstract] [Full Text] [Related]
12. Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.
Mirochnik Y; Rubenstein M; Guinan P
J Drug Target; 2007 Jun; 15(5):342-50. PubMed ID: 17541843
[TBL] [Abstract][Full Text] [Related]
13. A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer.
Frigerio B; Fracasso G; Luison E; Cingarlini S; Mortarino M; Coliva A; Seregni E; Bombardieri E; Zuccolotto G; Rosato A; Colombatti M; Canevari S; Figini M
Eur J Cancer; 2013 Jun; 49(9):2223-32. PubMed ID: 23433847
[TBL] [Abstract][Full Text] [Related]
14. Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.
Chen R; Zhao Y; Huang Y; Yang Q; Zeng X; Jiang W; Liu J; Thrasher JB; Forrest ML; Li B
Prostate; 2015 May; 75(6):593-602. PubMed ID: 25620467
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded.
Todorova K; Ignatova I; Tchakarov S; Altankova I; Zoubak S; Kyurkchiev S; Mincheff M
Cancer Immun; 2005 Jan; 5():1. PubMed ID: 15641767
[TBL] [Abstract][Full Text] [Related]
16. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
[TBL] [Abstract][Full Text] [Related]
18. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto JT; Suffoletto BP; Berzin TM; Qiao CH; Lin S; Tong WP; May F; Mukherjee B; Heston WD
Clin Cancer Res; 1996 Sep; 2(9):1445-51. PubMed ID: 9816319
[TBL] [Abstract][Full Text] [Related]
20. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
